Cell and gene Therapy Supply Chain Software Market Size, Share & Trends Analysis Report By Process Component (Sample Collection And Processing Components, Manufacturing Domains, Logistics Components, And Patient Identification And Treatment Follow-Up Components), Type Of Software, Mode Of Deployment, Type Of End-User, And Scale Of Operation, Region And Segment Forecasts, 2025-2034
Segmentation of Cell & Gene Therapy Supply Chain Software Market -
Cell & Gene Therapy Supply Chain Software Market By Process Component-
- Sample Collection and Processing Component
- Manufacturing Component
- Logistics Component
- Patient Identification and Treatment Follow-up Component
Cell & Gene Therapy Supply Chain Software Market By Type of Software-
- Enterprise Manufacturing System (EMS)
- Laboratory Information Management System (LIMS)
- Inventory Management System (IMS)
- Cell Orchestration Platform (COP)
- Quality Management System (QMS)
- Logistics Management System (LMS)
- Patient Management System (PMS)
Cell & Gene Therapy Supply Chain Software Market By Mode of Deployment-
- On-premises Deployment
- Cloud-based Deployment
Cell & Gene Therapy Supply Chain Software Market By Type of End-User-
- Pharmaceutical Companies
- Cell Therapy Labs
- Hospitals / Medical Centers
- Research Institutes / Biobanks
Cell & Gene Therapy Supply Chain Software Market By Scale of Operation-
- Clinical Scale
- Commercial Scale
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy Supply Chain Software Market Snapshot
Chapter 4. Global Cell and Gene Therapy Supply Chain Software Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Process Component Estimates & Trend Analysis
5.1. by Process Component & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Process Component:
5.2.1. Sample Collection and Processing Component
5.2.2. Manufacturing Component
5.2.3. Logistics Component
5.2.4. Patient Identification and Treatment Follow-up Component
Chapter 6. Market Segmentation 2: by Type of Software Estimates & Trend Analysis
6.1. by Type of Software & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Software:
6.2.1. Enterprise Manufacturing System (EMS)
6.2.2. Laboratory Information Management System (LIMS)
6.2.3. Inventory Management System (IMS)
6.2.4. Cell Orchestration Platform (COP)
6.2.5. Quality Management System (QMS)
6.2.6. Logistics Management System (LMS)
6.2.7. Patient Management System (PMS)
Chapter 7. Market Segmentation 3: by Mode of Deployment Estimates & Trend Analysis
7.1. by Mode of Deployment & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Mode of Deployment:
7.2.1. On-premises Deployment
7.2.2. Cloud-based Deployment
Chapter 8. Market Segmentation 4: by Scale of Operation Estimates & Trend Analysis
8.1. by Scale of Operation & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Scale of Operation:
8.2.1. Clinical Scale
8.2.2. Commercial Scale
Chapter 9. Market Segmentation 5: by End-User Estimates & Trend Analysis
9.1. by End-User & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-User:
9.2.1. Pharmaceutical Companies
9.2.2. Cell Therapy Labs
9.2.3. Hospitals / Medical Centers
9.2.4. Research Institutes / Biobanks
Chapter 10. Cell and Gene Therapy Supply Chain Software Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component,2021-2034
10.1.2. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.1.3. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.1.4. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.1.5. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.1.6. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.2. Europe
10.2.1. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.2.2. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.2.3. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.2.4. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.2.5. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.2.6. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.3. Asia Pacific
10.3.1. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.3.2. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.3.3. Asia-Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.3.4. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.3.5. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3.6. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.4. Latin America
10.4.1. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.4.2. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.4.3. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.4.4. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.4.5. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4.6. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.5.2. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.5.3. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.5.4. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.5.5. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5.6. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Azenta Life Sciences
11.2.2. Biocair
11.2.3. BioLife Solutions
11.2.4. CareDx
11.2.5. Cryoport
11.2.6. Lonza
11.2.7. NMDP BioTherapies
11.2.8. TraceLink
11.2.9. TrakCel
11.2.10. Veeva Systems
11.2.11. Emerson
11.2.12. LabVantage Solutions
11.2.13. Marken
11.2.14. MasterControl
11.2.15. QuickSTAT
11.2.16. Siemens
11.2.17. Stafa Cellular Therapy
11.2.18. Steiner
11.2.19. STEMSOFT Software
11.2.20. TECHNIDATA
11.2.21. Thermo Fisher Scientific
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cell And Gene Therapy Supply Chain Software Market, a rapidly growing sector, Size is valued at USD 269.3 Mn in 2024 and is predicted to reach USD 982
Cell And Gene Therapy Supply Chain Software Market is predicted to develop at a 14.0% CAGR during the forecast period for 2025-2034.
Veeva Systems, Emerson, Cryoport, Marken, MasterControl, Steiner, Siemens, Stafa Cellular Therapy, QuickSTAT, STEMSOFT Software, TECHNIDATA and Thermo
Process Component, Type Of Software, Mode Of Deployment, Type Of End-User, and Scale Of Operation are the key segments of the Cell and gene Therapy Su
North America region is leading the Cell and gene Therapy Supply Chain Software Market.